Skip to main content
Premium Trial:

Request an Annual Quote

Novacyt Raises $3.8M in Private Equity

NEW YORK (GenomeWeb) – Novacyt today announced it has raised 3.1 million ($3.8 million) in a private equity placement.

Institutional investor Alto Invest joined existing investors in the funding round.

"The fundraising will enable the company to significantly accelerate the commercialization of the world-class cytology platform, NovaPrep," Novacyt CEO Graham Mullis said in a statement. "In particular, it enables the company to expand its global commercial channels, including launching in key new markets in the next few months."

The firm said in a statement that it will use the funds to build sales in China and other new markets in Asia, as well as develop molecular diagnostics for infectious disease, beginning with new products targeting fungal infections including Aspergillus and Pneumocystis.

In May, Paris-based Novacyt bought diagnostic products and services firm Lab21 for $34.1 million.


The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.